Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...
A dietary supplement used to build muscle – or prevent muscle loss as a result of ageing or illness – is to be trialled as a potential treatment for chronic liver disease.
Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...
A dietary supplement used to build muscle - or prevent muscle loss as a result of ageing or illness - is to be trialled as a potential treatment for ...
Hepatic encephalopathy is a liver disease that affects the brain. Learn how a new treatment can treat the disease and prevent ...
SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.
A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) ...
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
A Cleveland Clinic study reveals that bariatric surgery significantly reduces the risk of serious liver complications in ...
CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic ...
In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated ...
Multidisciplinary care is needed to ensure positive maternal and fetal health outcomes, especially in complex or high-risk ...